Reposted by Justo P. Castaño 🔬🧬🧫 #SinCienciaNoHayFuturo
Justo P. Castaño 🔬🧬🧫 #SinCienciaNoHayFuturo
@justocastano.bsky.social
1.1K followers 1.6K following 211 posts
Father, husband, scientist. Cell Biology Professor. IMIBIC - UCO Editor in Chief Endocrine Oncology @endocrineoncology.bsky.social Biomedical research: hormones & cancer, RNA splicing Pancreatic Cancer, Neuroendocrine tumors NETs 🦓 Always with a smile 😃
![[Endocrine Oncology logo]
Now indexed in Web of ScienceTM
SPECIAL COLLECTIONS
Bringing together research on key topics in endocrine oncology](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:ivhoanslteishzyswxdca5xy/bafkreih7e2ikpam5ueruyfeoeb3u3kp3xhg7scw27rzv6udoedxcwi5lxm)
![SPECIAL COLLECTION
Women in Neuroendocrine Tumour Science: Breaking Barriers and Building Legacies
-
NEW REVIEW
Functioning pancreatic neuroendocrine neoplasms: Diagnosis and current treatment
Panagiota Konstantakou, Ariadni Spyroglou, Marina Tsoli, Anna Angelousi, Gregory Kaltsas, Krystallenia I. Alexandraki
-
[Endocrine Oncology logo]](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:ivhoanslteishzyswxdca5xy/bafkreiathgrpr5svgei7t66yh6fuajsdgevkyjk5csta4wqnfyqop3xsem)
![[Endocrine Oncology logo]
-
NOW INDEXED IN Web of ScienceTM
-
[World map highlighting the locations of individuals in our reviewer board]
-
Introducing our new Editorial Board members
Behind every published paper is a community of experts](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:ivhoanslteishzyswxdca5xy/bafkreie2ll6j7oxdnencoyai5jzsc3s3h5dwlk2ytv453ho56rdabhezxi)
![[Endocrine Oncology logo]
Comprehensive somatic profiling of gastroenteropancreatic neuroendocrine neoplasms. By Chirayu Mohindroo et al.
Figure 2. Mutational heatmap of pathogenic and likely pathogenic variants across tumors from 111 patients. Each row represents a tumor sample, and each column represents a gene. The colored tiles indicate the presence of pathogenic or likely pathogenic mutations. Gray tiles indicate unavailable data for the corresponding variable and sample, except where otherwise specified in the color legend. The heatmap illustrates the distribution and frequency of clinically relevant mutations across the cohort, alongside key clinical characteristics. Genes were grouped into broad functional categories according to their predominant biological roles described in the literature; these categories are descriptive and not mutually exclusive, as individual genes may participate in multiple biological pathways.
Endocr Oncol (2026) 6 (1): e260044. doi.org/10.1530/EO-26-0044.](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:ivhoanslteishzyswxdca5xy/bafkreiao3xvnkohfne7oi6jzpx6rr4ghh6yi4hirp5drcyiudghuqa2dp4)
![Corticotroph tumour progression 37 years after bilateral adrenalectomy with temozolomide-naive response to pembrolizumab
By Edward Mignone et al.
Figure 1. Top left: T1-weighted gadolinium-enhanced coronal magnetic resonance imaging (MRI) of the patient’s sella. Residual tumour in the right cavernous sinus (6 × 4 mm), 3 months after transsphenoidal resection, before pembrolizumab. Top right: reduction in size of tumour remnant in the right cavernous sinus (4 × 4 mm) after 15 months of pembrolizumab and 12 months after radiosurgery. Bottom: adrenocorticotropic hormone (ACTH) trend in relation to interventions. ACTH initially declined but then rose after transsphenoidal resection, followed by a significant decline at 2 weeks after radiotherapy completion and 3 months after the initiation of pembrolizumab...Endocr Oncol (2026) 6 (1): e260064. doi.org/10.1530/EO-26-0064.
[Endocrine Oncology logo]](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:ivhoanslteishzyswxdca5xy/bafkreiho7wtkxurr2ffohrhhi6spacehy63rgr36z567poubs25sr6uqku)
![Cytological biomarkers and risk of malignancy in indeterminate thyroid nodules: a systematic review and meta-analysis. By Trille Moberg Fagerhaug et al.
[Endocrine Oncology logo]
Figure 3. Descriptive forest plot showing DOR of markers differentiating benign from malignant nodules with indeterminate FNAC samples. (A) Galectin-3, (B) HBME-1, (C) BRAF, and (D) Galectin-3/HBME-1 co-expression.
Endocr Oncol (2026) 6 (1): e250097. doi.org/10.1530/EO-25-0097.](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:ivhoanslteishzyswxdca5xy/bafkreiehnsye6tvordd3jix7naaotlfqq5ar22mnr5trhql7lq2bechm6u)
![[Endocrine Oncology logo] Current Evidence Across the Treatment Spectrum of Adrenocortical Carcinoma: A Comprehensive Scoping Review. By Angélica María González-Clavijo et al. Figure 1. Evidence map of treatment strategies in adrenocortical carcinoma (ACC). This figure summarizes the distribution, quantity, and direction of available evidence across the five clinical domains examined in this scoping review: surgery, adjuvant therapy, metastatic disease, recurrence, and hormone excess. Each bubble represents a specific intervention or evidence focus within a clinical domain. Bubble size reflects the number of contributing studies, fill color indicates the overall direction of evidence, and shape identifies whether randomized evidence was available. The x-axis groups interventions according to clinical domain, whereas the y-axis displays the principal intervention or evidence category evaluated...Endocr Oncol EO-26-0079. doi.org/10.1530/EO-26-0079](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:ivhoanslteishzyswxdca5xy/bafkreigabeetro7bbc3oywjcgkdkonewnzlegxn6r5dsblk7vndrakiaru)
